SUVEN.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 02:54):

Stats
Today's Volume	82 065.00
Average Volume	197 220
Market Cap	22.15B
EPS	INR0 ( 2024-05-07 )
Next earnings date	( INR0 ) 2024-08-06
Last Dividend	INR1.382 ( 2019-02-14 )
Next Dividend	INR0 ( N/A )
P/E	-21.29
ATR14	INR0.122 (0.12%)

Volume Correlation

Long: -0.16 (neutral)

Short: -0.39 (neutral)

Signal:(34.505) Neutral

Suven Life Sciences Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Suven Life Sciences Correlation - Currency/Commodity

-0.39
( neutral )

-0.40
( neutral )

-0.47
( neutral )

-0.51
( weak negative )

0.45
( neutral )

0.61
( weak )

Suven Life Sciences Financials

Annual	2022
Revenue:	INR135.39M
Gross Profit:	INR129.74M (95.82 %)
EPS:	INR-6.63

FY	2022
Revenue:	INR135.39M
Gross Profit:	INR129.74M (95.82 %)
EPS:	INR-6.63

FY	2022
Revenue:	INR118.44M
Gross Profit:	INR118.44M (100.00 %)
EPS:	INR-8.86

FY	2021
Revenue:	INR134.78M
Gross Profit:	INR134.78M (100.00 %)
EPS:	INR-5.67

Financial Reports:

No articles found.

Suven Life Sciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Suven Life Sciences Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 1.875 - No dividend growth expected in the near future

Information

First Dividend	INR0.230	2004-09-10
Last Dividend	INR1.382	2019-02-14
Next Dividend	INR0	N/A
Payout Date	2019-02-25
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR8.02	--
Avg. Dividend % Per Year	0.00%	--
Score	0.66	--
Div. Sustainability Score	0
Div.Growth Potential Score	1.875
Div. Directional Score	0	--

Next Divdend (Est)
(2024-11-12)

INR0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

0.66

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR1.382	0.73%
2019	INR1.382	0.60%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TORNTPHARM.NS	Dividend Junior	2023-06-23	Annually	22	0.85%
PFS.NS	Dividend Junior	2023-09-05	Sporadic	14	1.84%
JAYBARMARU.NS	Dividend Junior	2023-09-08	Annually	23	1.48%
DCMSHRIRAM.NS	Dividend Junior	2023-07-18	Semi-Annually	23	1.23%
SKFINDIA.NS	Dividend Junior	2023-06-28	Annually	22	0.93%
MEDICAMEQ.NS	Ex Dividend Junior	2023-09-20	Annually	3	0.02%
GULFOILLUB.NS	Dividend Junior	2023-08-25	Annually	11	2.19%
BBTC.NS	Dividend Junior	2023-09-22	Annually	22	0.08%
PRIMESECU.NS	Dividend Junior	2023-06-06	Sporadic	19	1.83%
KANSAINER.NS	Dividend Junior	2023-05-25	Annually	21	0.49%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-8.91	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.298	1.500	-4.42	-6.63	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-652.21	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	0.611	2.00	9.80	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.611	2.00	9.69	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	-1.686	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-9.99	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-4.38

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-21.66	1.000	-2.29	0	[1 - 100]
returnOnEquityTTM	-0.298	2.50	-2.84	-6.63	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.611	2.00	9.80	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.611	2.00	9.80	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.314	1.500	-1.240	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	1.119	1.000	10.00	0	[0.1 - 0.5]
Total Score				1.875

Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.